In-silico analysis of multiepitope based vaccine targeting respiratory viruses SARS, MERS and SARS-CoV-2

BACKGROUND: Recurrent outbreaks of respiratory viruses like SARS-CoV (severe acute respiratory syndrome-coronavirus, 2002), MERS (Middle East respiratory syndrome, 2012) including the ongoing SARS-CoV-2 (2019) pandemic warrants for a single-broad-spectrum vaccine against these respiratory viruses. METHODS: In the present study, phylogenetic analysis followed by in-silico identification of vaccine candidates for SARS, MERS and SARS- CoV-2 was performed by exploiting T-cell and B-cell mapping to ascertain the best possible epitopes for effector humoral- and cell-mediated immune response. Further, population-coverage analysis of the identified epitopes followed by the designing of chimera of epitope-based vaccine was done using linkers and adjuvants. Docking study was done to appraise the interaction of the proposed vaccine with ACE2 (angiotensin converting enzyme-2) receptor (SARS and SARS-CoV-2) and HLA-B7 (human leukocyte antigen) receptor (MERS). The stability of the vaccine chimera was confirmed by molecular dynamics performed for 20 ns;this was followed by codon optimization and in-silico cloning. RESULTS: Phylogenetic analysis revealed similarity among SARS-CoV-2, SARS-CoV and bat SARS-like coronavirus. Both, SARS-CoV and SARS-CoV-2 were from different class than MERS, whereas SARS-CoV-2 showed more relatedness with Bat SARS-like coronaviruses. The most suitable epitopes found were LSFELLNAPATVCGP (SARS), LVTLAILTALRLCAY (SARS-CoV-2) and YTSAFNWLL (MERS) with nearly 98% population coverage. Molecular docking followed by simulation studies revealed high number of hydrogen bonds, stable RMSD values and acceptable RMSF flexibility scores, indicating stable interactions of the vaccine with ACE2 and MHC receptors (Major histocompat-ibility complex). Expression of the designed multiepitope vaccine in E. coli (Escherichia coli) expression system was confirmed by in-silico cloning/codon optimization. CONCLUSIONS: Further, in-vitro and in-vivo experimental validation studies are required to endorse our current findings. [ FROM AUTHOR] Copyright of Minerva Biotechnology & Biomolecular is the property of Edizioni Minerva Medica and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full . (Copyright applies to all s.)

[1]  Fuxun Yu,et al.  Contriving Multi-Epitope Subunit of Vaccine for COVID-19: Immunoinformatics Approaches , 2020, Frontiers in Immunology.

[2]  Md. Shahedur Rahman,et al.  Designing a multi-epitope vaccine against SARS-CoV-2: an immunoinformatics approach , 2020, Journal of biomolecular structure & dynamics.

[3]  Amjad Ali,et al.  Designing Multi-Epitope Vaccines to Combat Emerging Coronavirus Disease 2019 (COVID-19) by Employing Immuno-Informatics Approach , 2020, Frontiers in Immunology.

[4]  F. Castiglione,et al.  A candidate multi-epitope vaccine against SARS-CoV-2 , 2020, Scientific Reports.

[5]  Colin Renfrew,et al.  Phylogenetic network analysis of SARS-CoV-2 genomes , 2020, Proceedings of the National Academy of Sciences.

[6]  Yumeng Yan,et al.  The HDOCK server for integrated protein–protein docking , 2020, Nature Protocols.

[7]  S. Bose,et al.  Immunoinformatics‐aided identification of T cell and B cell epitopes in the surface glycoprotein of 2019‐nCoV , 2020, Journal of medical virology.

[8]  Lanjuan Li,et al.  Molecular Characteristics, Functions, and Related Pathogenicity of MERS-CoV Proteins , 2019, Engineering.

[9]  Marc Hafner,et al.  A Multi-center Study on the Reproducibility of Drug-Response Assays in Mammalian Cell Lines , 2019, Cell systems.

[10]  T. Bhardwaj,et al.  Comparative assessment of the therapeutic drug targets of C. botulinum ATCC 3502 and C. difficile str. 630 using in silico subtractive proteomics approach , 2019, Journal of cellular biochemistry.

[11]  Jie Cui,et al.  Origin and evolution of pathogenic coronaviruses , 2018, Nature Reviews Microbiology.

[12]  R. Mandal,et al.  Inhibition of C298S mutant of human aldose reductase for antidiabetic applications: Evidence from in silico elementary mode analysis of biological network model , 2018, Journal of cellular biochemistry.

[13]  R. Mandal,et al.  Aspartate‐β‐semialdeyhyde dehydrogenase as a potential therapeutic target of Mycobacterium tuberculosis H37Rv: Evidence from in silico elementary mode analysis of biological network model , 2018, Journal of cellular biochemistry.

[14]  Wei Li,et al.  ElliPro: a new structure-based tool for the prediction of antibody epitopes , 2008, BMC Bioinformatics.

[15]  Wei Xu,et al.  A chimeric multi-epitope DNA vaccine elicited specific antibody response against severe acute respiratory syndrome-associated coronavirus which attenuated the virulence of SARS-CoV in vitro , 2008, Immunology Letters.

[16]  Krishna Shankara Narayanan,et al.  SARS coronavirus accessory proteins , 2007, Virus Research.

[17]  Morten Nielsen,et al.  Large-scale validation of methods for cytotoxic T-lymphocyte epitope prediction , 2007, BMC Bioinformatics.

[18]  Sudipto Saha,et al.  Prediction of continuous B‐cell epitopes in an antigen using recurrent neural network , 2006, Proteins.

[19]  John Sidney,et al.  Predicting population coverage of T-cell epitope-based diagnostics and vaccines , 2006, BMC Bioinformatics.